7/12/2010

Infinity Pharmaceuticals bought global rights to Intellikine's potential treatments for inflammatory and autoimmune diseases for $13.5 million. Intellikine could also receive as much as $475 million for the molecules, which work by targeting a type of immune system enzymes.

Related Summaries